Theodore Alan Huizenga Sells 967 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stock

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) CAO Theodore Alan Huizenga sold 967 shares of the company’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $42.10, for a total transaction of $40,710.70. Following the completion of the sale, the chief accounting officer now owns 50,265 shares of the company’s stock, valued at approximately $2,116,156.50. This represents a 1.89 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Ultragenyx Pharmaceutical Stock Down 0.4 %

Shares of NASDAQ RARE traded down $0.16 during trading hours on Tuesday, hitting $41.10. The company had a trading volume of 1,385,598 shares, compared to its average volume of 779,217. The firm’s 50 day moving average is $42.86 and its 200-day moving average is $49.03. The stock has a market capitalization of $3.80 billion, a P/E ratio of -6.48 and a beta of 0.60. Ultragenyx Pharmaceutical Inc. has a 1-year low of $37.02 and a 1-year high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.32) by ($0.07). Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. The business had revenue of $164.88 million during the quarter, compared to the consensus estimate of $163.23 million. On average, sell-side analysts predict that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have issued reports on RARE. Piper Sandler boosted their target price on Ultragenyx Pharmaceutical from $135.00 to $140.00 and gave the company an “overweight” rating in a research note on Monday, January 13th. Wedbush reissued a “neutral” rating and set a $48.00 target price (up from $46.00) on shares of Ultragenyx Pharmaceutical in a research note on Monday, January 13th. Royal Bank of Canada restated an “outperform” rating and set a $77.00 target price on shares of Ultragenyx Pharmaceutical in a report on Wednesday, November 6th. Canaccord Genuity Group raised their price objective on shares of Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the stock a “buy” rating in a report on Tuesday, February 18th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $118.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $93.50.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Ultragenyx Pharmaceutical in the 4th quarter valued at approximately $5,505,000. Mackenzie Financial Corp grew its position in shares of Ultragenyx Pharmaceutical by 275.6% in the 4th quarter. Mackenzie Financial Corp now owns 16,115 shares of the biopharmaceutical company’s stock valued at $678,000 after buying an additional 11,825 shares during the last quarter. GF Fund Management CO. LTD. bought a new stake in Ultragenyx Pharmaceutical in the fourth quarter valued at approximately $82,000. Frazier Life Sciences Management L.P. raised its stake in Ultragenyx Pharmaceutical by 3.9% during the fourth quarter. Frazier Life Sciences Management L.P. now owns 658,715 shares of the biopharmaceutical company’s stock worth $27,712,000 after buying an additional 25,000 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Ultragenyx Pharmaceutical by 13.9% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 202,376 shares of the biopharmaceutical company’s stock valued at $8,514,000 after buying an additional 24,620 shares during the period. 97.67% of the stock is owned by institutional investors.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.